kabutan

SAPPORO CLINICAL LABORATORY INC., First Half Ordinary Profit Increases by 16%, July-September Ordinary Profit Increases by 12%

Fri Nov 8, 2024 3:30 pm JST Earnings

9776 SAPPORO CLINICAL LABORATORY INC. 【J-GAAP】

Earnings Report

SAPPORO CLINICAL LABORATORY INC. <9776> [TSE-S] announced its financial results after the market closed on November 8th (15:30). The consolidated ordinary profit for the cumulative second quarter of the fiscal year ending March 2025 (April to September) increased by 15.9% from the same period last year, reaching 343 million yen. The progress rate against the 493 million yen full-year plan was 69.6%, also surpassing the five-year average of 48.6%.

Based on the first-half performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated ordinary profit for the October to March period (second half) is expected to drop by 31.2% from the same period last year to 150 million yen.

In the most recent three-month period, from July to September (2Q), the consolidated ordinary profit grew by 11.6% from the same period last year, reaching 241 million yen. The operating profit margin improved from 4.4% in the same period last year to 4.8%.

Kabutan News

Actual Results

Accumulated Results 2nd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Apr - Sep, 2022 9,964 492 589 258 77.4 50.8 Nov 9, 2022 J-GAAP
Apr - Sep, 2023 9,862 291 296 226 67.9 57.6 Nov 10, 2023 J-GAAP
Apr - Sep, 2024 9,996 337 343 222 70.9 69.6 Nov 8, 2024 J-GAAP
YoY +1.4% +15.8% +15.9% -1.8% +4.3%

First Half Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2024 Guidance 9,996 337 343 222 71.2 0 Nov 1, 2024 J-GAAP
Apr - Sep, 2024 Results 9,996 337 343 222 70.9 0 Nov 8, 2024 J-GAAP
Revision Rate 0.0% 0.0% 0.0% 0.0% -0.4%

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2023 9,820 243 218 154 46.3 23 May 13, 2024 J-GAAP
Oct - Mar, 2024 Guidance 9,803 163 150 98 31.4 23 Nov 1, 2024 J-GAAP
YoY -0.2% -32.9% -31.2% -36.4% -32.1%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2023 20,127 1,008 1,159 568 170.5 23 May 12, 2023 J-GAAP
Mar, 2024 19,682 534 514 380 114.1 23 May 13, 2024 J-GAAP
Mar, 2025 Guidance 19,799 500 493 320 102.6 23 May 13, 2024 J-GAAP
YoY +0.6% -6.4% -4.1% -15.8% -10.1%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Jul - Sep, 2023 4,940 216 216 221 66.4 4.4 Nov 10, 2023 J-GAAP
Oct - Dec, 2023 4,990 123 121 85 25.6 2.5 Feb 9, 2024 J-GAAP
Jan - Mar, 2024 4,830 120 97 69 20.7 2.5 May 13, 2024 J-GAAP
Apr - Jun, 2024 4,999 98 102 56 17.9 2.0 Aug 5, 2024 J-GAAP
Jul - Sep, 2024 4,997 239 241 166 53.0 4.8 Nov 8, 2024 J-GAAP
YoY +1.2% +10.6% +11.6% -24.9% -20.2%

Related Articles